FY2028 Earnings Forecast for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Leerink Partnrs reduced their FY2028 earnings per share (EPS) estimates for Axsome Therapeutics in a research note issued on Friday, February 21st. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $9.30 per share for the year, down from their prior estimate of $9.70. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2029 earnings at $16.05 EPS.

AXSM has been the subject of several other reports. Leerink Partners upped their price objective on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, February 10th. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Bank of America boosted their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Robert W. Baird set a $132.00 target price on shares of Axsome Therapeutics in a report on Monday, February 3rd. Finally, Mizuho lifted their price target on shares of Axsome Therapeutics from $137.00 to $195.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 11th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $158.79.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $127.09 on Monday. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The firm has a market capitalization of $6.20 billion, a PE ratio of -21.22 and a beta of 1.05. The business’s fifty day moving average price is $102.78 and its 200 day moving average price is $95.62.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Hedge Funds Weigh In On Axsome Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. BVF Inc. IL boosted its holdings in Axsome Therapeutics by 32.7% during the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock worth $117,444,000 after buying an additional 342,064 shares in the last quarter. FMR LLC lifted its position in shares of Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after acquiring an additional 185,951 shares during the period. Geode Capital Management LLC boosted its stake in shares of Axsome Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 912,538 shares of the company’s stock worth $77,228,000 after acquiring an additional 4,079 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Axsome Therapeutics by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock worth $66,750,000 after acquiring an additional 8,125 shares during the period. Finally, Invesco Ltd. increased its stake in Axsome Therapeutics by 10.8% in the 4th quarter. Invesco Ltd. now owns 692,464 shares of the company’s stock valued at $58,589,000 after purchasing an additional 67,285 shares in the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.